Nigeria: Emerging and Re-Emerging Diseases - Call for Timely Public Health Response in Nigeria
[Guardian] At present, the World Health Organisation (WHO) is monitoring a couple of infectious diseases, including: Ebola, Lassa fever, Severe Acute Respiratory Syndrome (SARS), Acquired Immune Deficiency Syndrome (AIDS), Haemorrhagic fever, West Nile Virus, and Lyme disease. The rate of re-emergence of infectious disease has been on the increase. Diseases such as cholera, tuberculosis, Influenza (flu), hepatitis and staphylococcus infections thought to have been controlled are re-emerging. A majority of the agents
Publication date: Available online 9 October 2020Source: Reumatología Clínica (English Edition)Author(s): Lina María Saldarriaga Rivera, Daniel Fernández Ávila, Wilson Bautista Molano, Daniel Jaramillo Arroyave, Alain Jasaf Bautista Ramírez, Adriana Díaz Maldonado, Jorge Hernán Izquierdo, Edwin Jáuregui, María Constanza Latorre Muñoz, Juan Pablo Restrepo, Juan Sebastián Segura Charry
Authors: Hui KK PMID: 33034297 [PubMed - as supplied by publisher]
Publication date: Available online 9 October 2020Source: Neurología (English Edition)Author(s): G. Alvarez Bravo, L. RamióTorrentà
Publication date: Available online 9 October 2020Source: Neurología (English Edition)Author(s): N. Morollón, R. Belvís, A. De Dios, N. Pagès, C. González-Oria, G. Latorre, S. Santos-Lasaosa
Publication date: Available online 10 October 2020Source: Journal of Hospital InfectionAuthor(s): Hisakazu Yano, Ryuichi Nakano, Yuki Suzuki, Akiyo Nakano, Kei Kasahara, Hiroshi Hosoi
Publication date: Available online 10 October 2020Source: Journal of Clinical and Experimental HepatologyAuthor(s): Pramod Kumar, Anand Kulkarni, Mithun Sharma, Padaki Nagaraja Rao
[This Day] Asaba -- Delta State Government has launched the HIV Self-Testing Programme with a vow to scale up all response measures for arresting the relatively high HIV prevalence rate in the state, which places Delta as being among the highest in the country.
Authors: Tamai H, Shingaki N, Ida Y, Shimizu R, Maeshima S, Okamura J, Kawashima A, Nakao T, Hara T, Matsutani H, Nishikawa I, Higashi K Abstract BACKGROUND: Although clinical use of sofosbuvir plus ribavirin has been approved for patients infected with genotype 2 hepatitis C virus, patients ≥ 75-years-old have not been included in previous clinical trials. AIM: To evaluate the real-world safety and efficacy of sofosbuvir plus ribavirin for elderly patients (≥ 75-years-old) compared to nonelderly patients, we conducted a post-marketing prospective cohort study. METHODS: We treated 265 patients with ge...
CONCLUSION: DAAs are effective and safe in the treatment of recurrent HCV infection in LT recipients with history of HCC. Relapse to pre- and post-LT DAA therapy is associated with post-transplantation HCC recurrence. PMID: 33033569 [PubMed]